Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Herpes simplex encephalitis during treatment with tumor necrosis factor-alpha inhibitors.

Literature DB >> 19681709

Herpes simplex encephalitis during treatment with tumor necrosis factor-alpha inhibitors.

Russell D Bradford¹, April C Pettit, Patty W Wright, Mark J Mulligan, Larry W Moreland, David A McLain, John W Gnann, Karen C Bloch.

Abstract

We report 3 cases of herpes simplex virus encephalitis in patients receiving tumor necrosis factor-alpha (TNF-alpha) inhibitors for rheumatologic disorders. Although TNF-alpha inhibitors have been reported to increase the risk of other infectious diseases, to our knowledge, an association between anti-TNF-alpha drugs and herpes simplex virus encephalitis has not been previously described.

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2009 PMID： 19681709 PMCID： PMC3315107 DOI： 10.1086/605498

Source DB: PubMed Journal: Clin Infect Dis ISSN： 1058-4838 Impact factor: 9.079

16 in total

1. Patients with suspected herpes simplex encephalitis: rethinking an initial negative polymerase chain reaction result.

Authors: Ana A Weil; Carol A Glaser; Zahwa Amad; Bagher Forghani
Journal: Clin Infect Dis Date: 2002-03-21 Impact factor: 9.079

2. The management of encephalitis: clinical practice guidelines by the Infectious Diseases Society of America.

Authors: Allan R Tunkel; Carol A Glaser; Karen C Bloch; James J Sejvar; Christina M Marra; Karen L Roos; Barry J Hartman; Sheldon L Kaplan; W Michael Scheld; Richard J Whitley
Journal: Clin Infect Dis Date: 2008-08-01 Impact factor: 9.079

3. Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections.

Authors: D W Kimberlin; C Y Lin; R F Jacobs; D A Powell; L Corey; W C Gruber; M Rathore; J S Bradley; P S Diaz; M Kumar; A M Arvin; K Gutierrez; M Shelton; L B Weiner; J W Sleasman; T M de Sierra; S Weller; S J Soong; J Kiell; F D Lakeman; R J Whitley
Journal: Pediatrics Date: 2001-08 Impact factor: 7.124

Review 4. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.

Authors: Tim Bongartz; Alex J Sutton; Michael J Sweeting; Iain Buchan; Eric L Matteson; Victor Montori
Journal: JAMA Date: 2006-05-17 Impact factor: 56.272

5. Tumor necrosis factor inhibition and invasive fungal infections.

Authors: Scott G Filler; Michael R Yeaman; Donald C Sheppard
Journal: Clin Infect Dis Date: 2005-08-01 Impact factor: 9.079

6. Herpes simplex virus encephalitis: laboratory evaluations and their diagnostic significance.

Authors: A J Nahmias; R J Whitley; A N Visintine; Y Takei; C A Alford
Journal: J Infect Dis Date: 1982-06 Impact factor: 5.226

7. Herpes simplex virus type 2 infections of the central nervous system: A retrospective study of 49 patients.

Authors: Lars Haukali Omland; Bent Faber Vestergaard; Johan Heugh Wandall
Journal: Scand J Infect Dis Date: 2007-07-10

8. Diagnosis of herpes simplex encephalitis by magnetic resonance imaging and polymerase chain reaction assay of cerebrospinal fluid.

Authors: R B Domingues; M C Fink; A M Tsanaclis; C C de Castro; G G Cerri; M S Mayo; F D Lakeman
Journal: J Neurol Sci Date: 1998-05-07 Impact factor: 3.181

9. Tumor necrosis factor-alpha and interleukin-1 beta play a critical role in the resistance against lethal herpes simplex virus encephalitis.

Authors: Yan Sergerie; Serge Rivest; Guy Boivin
Journal: J Infect Dis Date: 2007-08-14 Impact factor: 5.226

10. Disseminated cutaneous Herpes Simplex Virus-1 in a woman with rheumatoid arthritis receiving infliximab: a case report.

Authors: Elizabeth Ann Justice; Sophia Yasmin Khan; Sarah Logan; Paresh Jobanputra
Journal: J Med Case Rep Date: 2008-08-26

23 in total

1. Atypical manifestations and poor outcome of herpes simplex encephalitis in the immunocompromised.

Authors: Ik L Tan; Justin C McArthur; Arun Venkatesan; Avindra Nath
Journal: Neurology Date: 2012-11-07 Impact factor: 9.910

2. Microglia and a functional type I IFN pathway are required to counter HSV-1-driven brain lateral ventricle enlargement and encephalitis.

Authors: Christopher D Conrady; Min Zheng; Nico van Rooijen; Douglas A Drevets; Derek Royer; Anthony Alleman; Daniel J J Carr
Journal: J Immunol Date: 2013-02-04 Impact factor: 5.422

3. Autoimmune-like syndromes during TNF blockade: does infection have a role?

Authors: Joerg C Prinz
Journal: Nat Rev Rheumatol Date: 2011-03-29 Impact factor: 20.543

Review 4. Viral diseases of the central nervous system.

Authors: Phillip A Swanson; Dorian B McGavern
Journal: Curr Opin Virol Date: 2015-02-12 Impact factor: 7.090

Review 5. Neurological Complications of Therapeutic Monoclonal Antibodies: Trends from Oncology to Rheumatology.

Authors: Chandler Gill; Stasia Rouse; Ryan D Jacobson
Journal: Curr Neurol Neurosci Rep Date: 2017-08-17 Impact factor: 5.081

6. Herpes Encephalitis: A Mortal Complication in a Patient Treated with Immunosuppressive Drugs because of Immune-Related Adverse Events after Ipilimumab Treatment.

Authors: Lieke van Montfort; Caroline M Loos; Monique Anten; Rob L H Jansen
Journal: Case Rep Oncol Date: 2017-12-18